The global smart pills market size is estimated to reach USD 3.64 billion by 2030, registering to grow at a CAGR of 11.3% from 2024 to 2030 according to a new report by Grand View Research, Inc. An increase in prevalence of diseases such as colorectal cancer and gastrointestinal disorders, expansion in the geographical reach of major players, rising cancer screening awareness programs, and expeditious FDA approvals are prime factors that are expected to drive the market growth over the forecast period.
Smart pills have transformed the landscape of small bowel, colon, and gastrointestinal endoscopy by providing a non-invasive and accurate method for visualizing distal duodenum, jejunum, small bowel, colon, gastrointestinal, and ileum. Smart pills are mostly used for screening and treatment of diseases such as colorectal cancer, gastroparesis, gastric ulcers, and gastroesophageal disorders.
Consumers of smart pills mostly include geriatric population, immobile patients, and patients with paralysis. Considering the steady rise in geriatric population around the globe, the demand for advanced medical devices will also increase as they offer a degree of convenience to patients. Established players in this market are enhancing their portfolio by upgrading existing devices. On the other hand, new players are focused on capturing emerging economies with breakthrough products that are both advanced and affordable.
Request a free sample copy or view report summary: Smart Pills Market Report
Capsule endoscopy dominated the market and accounted for the largest revenue share of 54.1% attributed to the painless procedure of diagnosing gastrointestinal disorders.
Celiac disease led the market and accounted for the largest revenue share 2023 driven by the increasing prevalence of gastrointestinal disorders and chronic diseases, such as cancer and diabetes, which necessitate innovative diagnostic and treatment solutions.
Small intestine dominated the market and held the largest revenue share in 2023 driven by the rising incidence of small intestine disorders, such as Crohn's and celiac diseases.
Outpatient facilities dominated the market with a share of 53.3% in 2023 owing to the rising demand for appropriate medicines and initiatives by governments to promote automated medication technologies in healthcare to minimize errors and risks.
The North America smart pills market dominated the global market and accounted for the largest revenue share of 37.5% in 2023.
Grand View Research has segmented the global smart pills market based on application, disease indication, target area, end-use, and region:
Smart Pills Application Outlook (Revenue, USD Million, 2018 - 2030)
Capsule Endoscopy
Drug Delivery
Vital Sign Monitoring
Smart Pills Disease Identification Outlook (Revenue, USD Million, 2018 - 2030)
Occult GI Bleeding
Crohn’s Disease
Small Bowel Tumors
Celiac Disease
Inherited Polyposis Syndromes
Neurological Disorders
Other Disease Indications
Smart Pills Target Area Outlook (Revenue, USD Million, 2018 - 2030)
Esophagus
Small Intestine
Large Intestine
Stomach
Smart Pills End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Outpatient Facilities
Smart Pills Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Smart Pills Market
Medtronic
Otsuka Holdings Co., Ltd.
Olympus Corporation
CapsoCam Plus
Pentax Medical
JINSHAN Science & Technology (Group) Co., Ltd.
Check-Cap Ltd.
etectRx
INTROMEDIC
Shenzen Jifu Medical Technology Co., Ltd
BodyCapUSA
"The quality of research they have done for us has been excellent..."